1287220-82-9

Upstream product

• 185677-00-3 2,4-dichloro-6-(2,2,2-trifluoroethoxy)-1,3,5-triazine 
• 18144-47-3 tert-butyl 4-aminobenzoate 

Downstream Products

• 1287220-83-0 tert-butyl 4-(4-(4-aminobenzylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1287220-78-3 tert-butyl 4-(4-(1-(3-bromophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1287220-79-4 tert-butyl 4-(4-(1-(3-(4-(tert-butoxycarbonylamino)butylamino)phenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoate 
• 1449410-55-2 ethyl 2-{[(2-(4-{[4-{[1-(4-chlorophenyl)cyclopropyl]amino}-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino}benzamido)cyclopentyl)methyl]amino}-2-oxoacetate 
• 1449410-56-3 (R)-2-[(tert-butoxycarbonyl)amino]-4-(4-{[4-{[1-(4-chlorophenyl)cyclopropyl]amino}-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino}benzamido)butanoic acid 
• 1449410-38-1 N-(3-amino-2,2-dimethylpropyl)-4-{[4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino}benzamide 
• 1622008-98-3 C₃₄H₃₄ClF₃N₈O₇ 
• 1620785-98-9 (S)-N-(1-amino-5-guanidino-1-oxopentan-2-yl)-4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzamide 
• 1620785-97-8 (S)-2-(4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzamido)-3-guanidinopropanoic acid 
• 1620785-96-7 (4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)phenyl)(2-iminoimidazolidin-1-yl)methanone 
• 1620786-24-4 N'-carbamoyl-4-(4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoyl)-N-cyclopentylpiperazine-1-carboximidamide 
• 1620786-23-3 4-(4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoyl)-N'-cyano-N-cyclopentylpiperazine-1-carboximidamide 
• 1620775-33-8 (S)-5-carboxy-5-(4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzamido)-N,N,N-trimethylpentan-1-aminium 
• 1620775-32-7 3-(4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzamido)-N,N,N-trimethylpropan-1-aminium 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infect

SPIRO BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

Compounds of Formula I, including pharmaceutically acceptable salts, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:

FUSED BICYCLIC OXALAMIDE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:

SQUARIC DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those i

AMMONIUM DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those i

GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula (I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infe

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV